GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

Main Inclusion Criteria: * Voluntarily participates in the study and provides written informed consent. * Male or female, age ≥ 18 and ≤ 80 years old * Has pathologically, cytologically, or radiologically confirmed unresectable hepatocellular carcinoma. * Has CNLC stage II to IIIa disease. * Has at least one measurable lesion according to mRECIST. * Child-Pugh class A or B. * ECOG performance status of 0 - 2. * Adequate hematologic and organ function. Main Exclusion Criteria: * Has a known allergy to the investigational product or related components, including human serum albumin and IL-2. * Has another incurable malignancy within 5 years before screening or concurrently. * Has a previous diagnosis of mixed or rare histologic subtypes, including fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or combined hepatocellular-cholangiocarcinoma. * Has received therapy aim to target lesion(s) within 12 weeks before screening. * Has hepatic encephalopathy within 4 weeks before screening. * Has clinically symptomatic ascites or pleural effusion requiring drainage, or has undergone thoracic or abdominal fluid drainage. * Has other active disease.